Business Segments · Goodwill
Human Pharmaceutical Products — Goodwill
Eli Lilly Human Pharmaceutical Products — Goodwill increased by 3.9% to $6.13B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 6.2%, from $5.77B to $6.13B. Over 5 years (FY 2020 to FY 2025), Human Pharmaceutical Products — Goodwill shows an upward trend with a 9.4% CAGR.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ4 2014
Last reportedQ1 2026
Rolls up toGoodwill
How to read this metric
Stable or growing goodwill suggests successful integration of acquisitions, while significant decreases signal impairment of acquired businesses.
Detailed definition
This represents the excess purchase price paid for acquisitions within the Human Pharmaceutical Products segment over th...
Peer comparison
Standard balance sheet item for all large-cap pharmaceutical companies that grow through inorganic acquisition strategies.
Metric ID:
lly_segment_human_pharmaceutical_products_goodwillHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.88B | $3.88B | $3.89B | $3.89B | $3.89B | $3.89B | $4.07B | $4.07B | $4.08B | $4.09B | $4.94B | $4.94B | $5.77B | $5.77B | $5.77B | $5.77B | $5.77B | $5.90B | $5.90B | $6.13B |
| QoQ Change | — | -0.0% | +0.2% | +0.0% | -0.0% | -0.0% | +4.7% | +0.0% | +0.1% | +0.2% | +20.9% | -0.0% | +16.8% | +0.0% | +0.0% | +0.0% | +0.0% | +2.2% | +0.0% | +3.9% |
| YoY Change | — | — | — | — | +0.2% | +0.2% | +4.7% | +4.7% | +4.8% | +5.0% | +21.3% | +21.3% | +41.4% | +41.2% | +16.8% | +16.8% | +0.0% | +2.2% | +2.2% | +6.2% |
Range$3.88B – $6.13B
CAGR+10.1%
Avg YoY Growth+11.8%
Median YoY Growth+4.9%
Current Streak8 quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's human pharmaceutical products — goodwill?
- Eli Lilly (LLY) reported human pharmaceutical products — goodwill of $6.13B in Q1 2026.
- How has Eli Lilly's human pharmaceutical products — goodwill changed year-over-year?
- Eli Lilly's human pharmaceutical products — goodwill increased by 6.2% year-over-year, from $5.77B to $6.13B.
- What is the long-term trend for Eli Lilly's human pharmaceutical products — goodwill?
- Over 5 years (2020 to 2025), Eli Lilly's human pharmaceutical products — goodwill has grown at a 9.4% compound annual growth rate (CAGR), from $3.77B to $5.90B.
- What does human pharmaceutical products — goodwill mean?
- The intangible value recorded on the balance sheet from past acquisitions within the pharmaceutical segment.